CoChat

A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder

Khan, Arifulla, Joyce, Mark, Atkinson, Sarah, Eggens, Ivan, Baldytcheva, Irina, Eriksson, Hans · 2011 · Journal of Clinical Psychopharmacology
Cited by 66

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

This study evaluated once-daily, extended-release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder (GAD). This was a 10-week (8-week active treatment/2-week posttreatment drug-discontinuation/tapering phase), double-blind, randomized, placebo-controlled study (D1448C00009). Primary end point was change from randomization at week 8 in Hamilton Anxiety Rating Scale (HAM-A) total score. Overall, 951 patients with GAD were randomized (quetiapine XR: 50 mg/d, n = 234; 150 mg/d, n = 241; 300 mg/d, n = 241; placebo, n = 235). At week 8, HAM-A total scores significantly (P < 0.001) improved versus placebo (-11.10) with quetiapine XR 50 mg/d (-13.31) and 150 mg/d (-13.54), but not 300 mg/d (-11.87; P = 0.240). At week 1, HAM-A total scores significantly improved versus placebo (-5.94) with quetiapine XR 50 mg/d (-7.47; P < 0.01), 150 mg/d (-8.19; P < 0.001), and 300 mg/d (-7.23; P < 0.01). Versus placebo at week 8, quetiapine XR 50 and 150 mg/d significantly improved HAM-A psychic (P < 0.01 and P < 0.001, respectively) and somatic (P < 0.001; P < 0.01, respectively) cluster scores, HAM-A response (≥ 50% total score reduction; P < 0.05), and Clinical Global Impression-Improvement categorical changes (P < 0.05). For quetiapine XR 150 mg/d, significant (P < 0.05) improvements were seen for HAM-A remission (total score, ≤ 7) and Clinical Global Impression-Severity of Illness scores. For quetiapine XR 300 mg/d, improvements in these secondary variables were not significantly different versus placebo. Pittsburgh Sleep Quality Index global scores improved with all 3 doses (quetiapine: XR 50 mg/d, -4.07 [P < 0.05]; 150 mg/d, -4.38 [P < 0.05]; 300 mg/d, -3.97 [P < 0.05], versus -3.31 with placebo). Adverse events (>10% with quetiapine XR) were dry mouth, somnolence, sedation, dizziness, headache, and fatigue. Quetiapine XR (50/150 mg/d) monotherapy was effective at week 8 in patients with GAD; symptom improvement was seen at week 1 for all doses (50/150/300 mg/d). Safety and tolerability were consistent with the known profile of quetiapine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e318224864d

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 41

  1. Grant, 2005, Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions., Psychol Med, 35, 1747, 10.1017/S0033291705006069 · DOI · Paper page
  2. Belanger, 2005, Generalized anxiety disorder and health care use., Can Fam Physician, 51, 1362
  3. Kessler, 1999, Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys., Am J Psychiatry, 156, 1915, 10.1176/ajp.156.12.1915 · DOI · Paper page
  4. Wittchen, 2002, Generalized anxiety and depression in primary care: prevalence, recognition, and management., J Clin Psychiatry, 63, 24
  5. Ninan, 2001, Dissolving the burden of generalized anxiety disorder., J Clin Psychiatry, 62, 5
  6. Bandelow, 2008, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision., World J Biol Psychiatry, 9, 248, 10.1080/15622970802465807 · DOI · Paper page
  7. Ball, 2005, Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline., J Clin Psychiatry, 66, 94, 10.4088/JCP.v66n0113 · DOI · Paper page
  8. Ballenger, 2001, Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety., J Clin Psychiatry, 62, 53
  9. Gorman, 2003, Treating generalized anxiety disorder., J Clin Psychiatry, 64, 24
  10. Chouinard, 2004, Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound., J Clin Psychiatry, 65, 7
  11. Merideth, 2008, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalised anxiety disorder (GAD) abstract., Eur Neuropsychopharmacol, 18, S499, 10.1016/S0924-977X(08)70749-1 · DOI
  12. Magi, 2009, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalised anxiety disorder (GAD) asbtract., World J Biol Psychiatry, 10, 239
  13. Katzman, 2011, Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial., Int Clin Psychopharmacol, 26, 11, 10.1097/YIC.0b013e32833e34d9 · DOI · Paper page
  14. Richelson, 2000, Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds., Life Sci, 68, 29, 10.1016/S0024-3205(00)00911-5 · DOI · Paper page
  15. Nyberg, 2010, Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties., Eur Psychiatry, 25, 1446, 10.1016/S0924-9338(10)71429-2 · doi:10.1016/s0924-9338(10)71429-2
  16. Jensen, 2008, N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity., Neuropsychopharmacology, 33, 2303, 10.1038/sj.npp.1301646 · DOI · Paper page
  17. 2001, Helsinki: ethical principles for medical research involving human subjects (revised October 7, 2000)., HIV Clin Trials, 2, 92, 10.1310/GTFR-2DRX-M6YE-ELXR · DOI · Paper page
  18. Hamilton, 1959, The assessment of anxiety states by rating., Br J Med Psychol, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  19. Buysse, 1989, The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research., Psychiatry Res, 28, 193, 10.1016/0165-1781(89)90047-4 · DOI · Paper page
  20. Ritsner, 2005, Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients., Qual Life Res, 14, 1693, 10.1007/s11136-005-2816-9 · DOI · Paper page
  21. Barnes, 1989, A rating scale for drug-induced akathisia., Br J Psychiatry, 154, 672, 10.1192/bjp.154.5.672 · DOI · Paper page
  22. Simpson, 1970, A rating scale for extrapyramidal side effects., Acta Psychiatr Scand Suppl, 212, 11, 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
  23. Hoehn-Saric, 1988, Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms., J Clin Psychiatry, 49, 293
  24. Rickels, 1993, Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam., Arch Gen Psychiatry, 50, 884, 10.1001/archpsyc.1993.01820230054005 · DOI · Paper page
  25. Rocca, 1997, Paroxetine efficacy in the treatment of generalized anxiety disorder., Acta Psychiatr Scand, 95, 444, 10.1111/j.1600-0447.1997.tb09660.x · DOI · Paper page
  26. Greenwood, 2008, Anxiety-like behaviors produced by acute fluoxetine administration in male Fischer 344 rats are prevented by prior exercise., Psychopharmacology (Berl), 199, 209, 10.1007/s00213-008-1167-y · DOI
  27. Papadimitriou, 2005, Sleep disturbance in anxiety disorders., Int Rev Psychiatry, 17, 229, 10.1080/09540260500104524 · DOI · Paper page
  28. Benca, 2001, Consequences of insomnia and its therapies., J Clin Psychiatry, 62, 33
  29. Maier, 2000, Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity?, Acta Psychiatr Scand, 101, 29, 10.1034/j.1600-0447.2000.101001029.x · DOI · Paper page
  30. Liebowitz, 2010, Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial., Depress Anxiety, 27, 964, 10.1002/da.20740 · DOI · Paper page
  31. Katila, 2009, Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD) abstract., World J Biol Psychiatry, 10, 225
  32. Bortnick, 2011, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study published online ahead of print August 4, 2010., J Affect Disord, 128, 83, 10.1016/j.jad.2010.06.031 · DOI
  33. Cutler, 2009, Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study., J Clin Psychiatry, 70, 526, 10.4088/JCP.08m04592 · DOI · Paper page
  34. Weisler, 2009, Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study., CNS Spectr, 14, 299, 10.1017/S1092852900020307 · DOI · Paper page
  35. El-Khalili, 2010, Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study., Int J Neuropsychopharmacol, 13, 917, 10.1017/S1461145710000015 · DOI · Paper page
  36. Kahn, 2007, Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study., J Clin Psychiatry, 68, 832, 10.4088/JCP.v68n0603 · DOI · Paper page
  37. Casey, 2006, Implications of the CATIE trial on treatment: extrapyramidal symptoms., CNS Spectr, 11, 25, 10.1017/S1092852900026651 · DOI
  38. Barnes, 1998, Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia., Int Clin Psychopharmacol, 13, S49, 10.1097/00004850-199803003-00009 · DOI
  39. Sachdev, 2004, Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study., Aust N Z J Psychiatry, 38, 445, 10.1080/j.1440-1614.2004.01382.x · DOI
  40. Lane, 1998, SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment., J Psychopharmacol, 12, 192, 10.1177/026988119801200212 · DOI · Paper page
  41. Harvey, 1995, Clinical implications of antidepressant drug effects on sexual function., Ann Clin Psychiatry, 7, 189, 10.3109/10401239509149625 · DOI

Cited by

See all 66

Metadata

Authors
Khan, A., Joyce, M., Atkinson, S., Eggens, I., Baldytcheva, I., & Eriksson, H.
Venue
Journal of Clinical Psychopharmacology
Published
2011-08
Volume
31
Issue
4
Pages
418-428
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1965144024
Cited by
66
References
12
FWCI
10.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder. https://app.cochat.ai/papers/10.1097/jcp.0b013e318224864d
The paper
Khan, A., Joyce, M., Atkinson, S., Eggens, I., Baldytcheva, I., & Eriksson, H. (2011). A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318224864d

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.